Publication

Article

Pharmaceutical Executive

Pharmaceutical Executive-01-01-2022
Volume42
Issue 1

Our View on 2022: Pharm Exec’s Annual Industry Outlook

Follow the links below to read about each trend:

Logistics - Julian Upton

Psychedelics - Elaine Quilici

Immunotherapies - Elaine Quilici

Social Influence - Fran Pollaro

Patient Engagement - Andy Studna

Health Plan Burdens - Lisa Henderson

Corporate Branding - Fran Pollaro

Chinese Biotech - Julian Upton

Download Issue PDF
Articles in this issue
Keeping Tabs on Quality: The Rise of Digital
Keeping Tabs on Quality: The Rise of Digital
China Invests in Building Biotech
Branding Takes on a New Look
Addressing Access Burdens
Meeting the Patient—Virtually
The Age of Influence
Boosting Immunotherapies
Pharma’s Psychedelic Experience
Supply Chain Procurement
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Breaking New Ground in Biopharma
Breaking New Ground in Biopharma
Biopharma Reaches New Heights as Calendar Turns
Biopharma Reaches New Heights as Calendar Turns
Empowered Patients Demand Digitalization, Make Mark on Pharma
Empowered Patients Demand Digitalization, Make Mark on Pharma
The Importance of Data Management in Taking Care of Business
The Importance of Data Management in Taking Care of Business
Too Many ‘Chiefs’ or Are Execs Simply Getting Their Due?
Too Many ‘Chiefs’ or Are Execs Simply Getting Their Due?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 1st 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Cell and Gene Therapy Check-in 2024
August 1st 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Earned Media and PBMs: Proactive Pathways for Image Boost
August 1st 2025

Earned Media and PBMs: Proactive Pathways for Image Boost

Michael Christel
Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through transparency, storytelling, and leveraging data to improve patient care.
Industry Outlook 2022
August 1st 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition
August 1st 2025

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition

Don Tracy, Associate Editor
Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.
Earned Media and ASCO: Provide Context Beyond the Data
August 1st 2025

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.